Breast Cancer Clinical Trial

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Summary

The primary objective of this study, sponsored by Travera LLC in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats. Cohorts include patients with stage III or IV breast cancer, stage III or IV lung cancer, active AML, and relapsed multiple myeloma. This pilot study will utilize samples from patients undergoing routine biopsy of their tumor as part of their clinical care (e.g. for clinical diagnosis, staging, DNA molecular analysis). This study will involve additional material from the same procedure the patient is already undergoing.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Sample collection or biopsy of tumor is clinically indicated as part of SOC
Prior to preceding onto therapy for treatment

Exclusion Criteria:

Unable to obtain sufficient sample

Study is for people with:

Breast Cancer

Estimated Enrollment:

130

Study ID:

NCT04985357

Recruitment Status:

Recruiting

Sponsor:

Travera Inc

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Columbus Regional Research Institute, John B. Amos Cancer Center
Columbus Georgia, 31904, United States More Info
Shelby Zikeli
Contact
706-321-0495

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

130

Study ID:

NCT04985357

Recruitment Status:

Recruiting

Sponsor:


Travera Inc

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.